MedTrace Logo

TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD

NCT00185796 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2015-03-18

No results posted yet for this study

Summary

To evaluate the feasibility and safety of TLI/ATG conditioning for allogeneic HCT for elderly patients with advanced stage MDS and MPD.

Conditions

Interventions

PROCEDURE

Total Lymphoid Irradiation (TLI)

TLI is administered ten times in 120cGy fractions on day -11 through day -7 and day -4 through day -1

PROCEDURE

Anti-Thymocyte Globulin as Conditioning (ATG)

Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg. Thymoglobulin doses will be based on the adjusted ideal body weight if the patient is greater than or equal to 15 kg over ideal body weight.

Sponsors & Collaborators

Principal Investigators

  • Robert Lowsky · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
49 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2014-04-30
Completion
2015-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00185796 on ClinicalTrials.gov